Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lassmann

Showing results (61-70 of 164) with videos related to

Pageof 17
Sort By:
World Journal of Radiology|July 30, 2014
Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emittersHinrich A Wieder, Michael Lassmann, Martin S Allen-Auerbach, et al.
Nuklearmedizin. Nuclear Medicine|August 21, 2018
[Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma]Frederik A Verburg, Frank Grünwald, Michael Lassmann, et al.
Zeitschrift Fur Medizinische Physik|August 20, 2023
Radiation-induced double-strand breaks by internal ex vivo irradiation of lymphocytes: Validation of a Monte Carlo simulation model using GATE and Geant4-DNAMaikol Salas-Ramirez, Lydia Maigne, Giovanna Fois, et al.
Zeitschrift Fur Medizinische Physik|May 16, 2006
The impact of PET and SPECT on dosimetry for targeted radionuclide therapyGlenn Flux, Manuel Bardies, Myriam Monsieurs, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4]Markus Dietlein, Wolfgang Eschner, Frank Grünwald, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patientsFrederik A Verburg, Michael Lassmann, Uwe Mäder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 14, 2010
EANM procedure guidelines for therapy of benign thyroid diseaseMarcel P M Stokkel, Daria Handkiewicz Junak, Michael Lassmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2010
In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancerMichael Lassmann, Heribert Hänscheid, Daniela Gassen, et al.
Medical Physics|August 10, 2013
A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculationMaría Fernández, Heribert Hänscheid, Thibault Mauxion, et al.
Endocrine-Related Cancer|March 25, 2005
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive reviewMarkus Luster, Francesco Lippi, Barbara Jarzab, et al.
Pageof 17

Showing results (61-70 of 164) with videos related to

Sort By:
Pageof 17
World Journal of Radiology|July 30, 2014
Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emittersHinrich A Wieder, Michael Lassmann, Martin S Allen-Auerbach, et al.
Nuklearmedizin. Nuclear Medicine|August 21, 2018
[Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma]Frederik A Verburg, Frank Grünwald, Michael Lassmann, et al.
Zeitschrift Fur Medizinische Physik|August 20, 2023
Radiation-induced double-strand breaks by internal ex vivo irradiation of lymphocytes: Validation of a Monte Carlo simulation model using GATE and Geant4-DNAMaikol Salas-Ramirez, Lydia Maigne, Giovanna Fois, et al.
Zeitschrift Fur Medizinische Physik|May 16, 2006
The impact of PET and SPECT on dosimetry for targeted radionuclide therapyGlenn Flux, Manuel Bardies, Myriam Monsieurs, et al.
Nuklearmedizin. Nuclear Medicine|June 29, 2016
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Version 4]Markus Dietlein, Wolfgang Eschner, Frank Grünwald, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 7, 2011
The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patientsFrederik A Verburg, Michael Lassmann, Uwe Mäder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 14, 2010
EANM procedure guidelines for therapy of benign thyroid diseaseMarcel P M Stokkel, Daria Handkiewicz Junak, Michael Lassmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 28, 2010
In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancerMichael Lassmann, Heribert Hänscheid, Daniela Gassen, et al.
Medical Physics|August 10, 2013
A fast method for rescaling voxel S values for arbitrary voxel sizes in targeted radionuclide therapy from a single Monte Carlo calculationMaría Fernández, Heribert Hänscheid, Thibault Mauxion, et al.
Endocrine-Related Cancer|March 25, 2005
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive reviewMarkus Luster, Francesco Lippi, Barbara Jarzab, et al.
Pageof 17